One-on-One with Dan Adelman of Alvine Pharmaceuticals

One-on-One with Dan Adelman of Alvine Pharmaceuticals

November 18, 2011

A gluten-free diet is great for celiac disease patients, but even the strictest adherents to dietary restrictions can experience flare ups or chronic symptoms.
 

Selecta Biosciences, Inc.

Selecta Biosciences Initiates Phase 1 Clinical Study of SEL-068, a First-in-Class Synthetic Nicotine Vaccine for Smoking Cessation and Relapse Prevention

Selecta Biosciences Initiates Phase 1 Clinical Study of SEL-068, a First-in-Class Synthetic Nicotine Vaccine for Smoking Cessation and Relapse Prevention

November 21, 2011

Watertown, MA – November 21, 2011 – Selecta Biosciences, Inc., a biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacodynamic profile of SEL-068, a nicotine vaccine candidate for smoking cessation and relapse prevention.

LS9

LS9 Significantly Expands Production

LS9 Significantly Expands Production

November 7, 2011

LS9, Inc., a technology leader in the development of renewable and sustainable products, today announced that it has successfully scaled its technology to the 20,000 liter scale, demonstrating continued progress in the scale-up and commercialization of its bio-based chemicals and fuels technology platform. From initial production of 1,000 liters at the Company's pilot plant in South San Francisco, California, LS9 has utilized a 20-fold step-up process to produce approximately one ton of a specific chemical for its strategic partner, Proctor & Gamble.

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Announces NIH Research Collaboration for Rare and Neglected Diseases

Concert Pharmaceuticals Announces NIH Research Collaboration for Rare and Neglected Diseases

November 15, 2011

Lexington, MA – Concert Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Agios Secures $78 Million in Oversubscribed Series C Financing

Agios Secures $78 Million in Oversubscribed Series C Financing

November 17, 2011

Cambridge, Mass. – Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced that is has secured $78 million in an oversubscribed Series C financing. The proceeds of this financing will be used to advance the company’s rapidly emerging portfolio of cancer metabolism therapeutics into the clinic and to expand research and development into inborn errors of metabolism (IEMs), a group of genetic disorders with high unmet medical need.
 

Celexion LLC

Celexion licensee BioAmber registers for IPO

Celexion licensee BioAmber registers for IPO

November 14, 2011

Today, BioAmber, a next generation chemicals company and licensee of Flagship portfolio company Celexion, announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common stock.

Theracrine Announces Publication Identifying Potential Novel Cancer Spread Target

Theracrine Announces Publication Identifying Potential Novel Cancer Spread Target

October 17, 2011

CAMBRIDGE, Mass. -- Theracrine, Inc., the first biopharmaceutical company focused on the discovery and development of novel therapeutics to treat cancer spread, today announced the publication of research from the lab of scientific founder Joan Massague, Ph.D. in Cancer Cell that elucidates the fundamental nature of cancer spread as well as the role of tumor-stromal interactions. The research specifically demonstrates the central role of VCAM-1 and VLA-4 in the survival and growth of metastatic breast cancer cells.

Novomer, Inc.

Novomer Wins ICIS Award for Innovation with Best Environmental Benefit

Novomer Wins ICIS Award for Innovation with Best Environmental Benefit

October 19, 2011

BOSTON, MA -- (Marketwire) - Novomer Inc., a sustainable materials company pioneering a family of high-performance plastics, polymers and other chemicals from renewable feedstocks such as carbon dioxide (CO2) and carbon monoxide (CO), today announced that it was selected for a prestigious 2011 ICIS Innovation Award. Lauded as the "Innovation with Best Environmental Benefit," the company's revolutionary technology was recognized for using CO2 as raw material to create high-performance polyols for coatings, adhesives, foams, composites and surfactant applications.

Selecta Biosciences, Inc.
BIND Therapeutics, Inc.

RUSNANO invests in Selecta Biosciences and BIND Biosciences to develop and commercialize vaccines and cancer drugs through expanded operations in Russia

RUSNANO invests in Selecta Biosciences and BIND Biosciences to develop and commercialize vaccines and cancer drugs through expanded operations in Russia

October 27, 2011

BIND and Selecta establish subsidiaries in Russia to access scientific and clinical expertise that will accelerate development of drugs and drug candidates.

BG Medicine, Inc.

BG Medicine, Inc. Announces Availability of Galectin-3 Testing Through Cleveland HeartLab, Inc.

BG Medicine, Inc. Announces Availability of Galectin-3 Testing Through Cleveland HeartLab, Inc.

October 27, 2011

WALTHAM, Mass. -- (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that Cleveland HeartLab, Inc. is now offering BGM Galectin-3TM testing services.